



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

## Chapter 5

# Role of Lysosomes in Cell Injury

LOUIS MARZELLA and HSIANG-KUANG LEE

---

<b>Introduction</b>	<b>168</b>
<b>Lysosomal Degradation Pathways</b>	<b>168</b>
Autophagy and Heterophagy	168
Degradative Capacity of Lysosomal Enzymes	171
<b>Regulation of Lysosomal Protein Degradation</b>	<b>173</b>
Enzyme Activity, Acidification	173
Amino Acids and Hormones	173
Effects of Growth, Age, pH, and Calcium Levels of Cells	174
<b>Functions of Lysosomal Enzymes</b>	<b>174</b>
Degradation of Proteins	174
Degradation of Lipoproteins and Membrane Lipids	175
<b>Lysosomes in Acute and Chronic Cell Injury</b>	<b>176</b>
Intracellular Leakage of Lysosomal Enzymes	176
Extracellular Release of Lysosomal Enzymes	176
Free Radical Injury	177
Intracellular Activation of Zymogen Enzymes by Crinophagy	177
Cytotoxic Drugs	178
Acidotropic Agents	178
Infections, Sepsis	179
Burn Injury	180
Myopathies and Denervation Injuries	181

---

**Principles of Medical Biology, Volume 13**  
**Cell Injury, pages 167-196.**  
Copyright © 1998 by JAI Press Inc.  
All rights of reproduction in any form reserved.  
ISBN: 1-55938-818-8

Starvation and Stress	181
Accumulation of Iron and Other Metals in Lysosomes	181
Accumulation of Pigments in Lysosomes	182
Storage Diseases	183
Atherosclerosis	184
<b>Lysosomal Degradation in Tumorigenesis and Tumor Metastasis</b>	<b>185</b>
Lysosomal Protein Degradation and Acidification in Cancer Cells	185
Role of Lysosomal Proteases in Tumor Invasion and Metastasis	185
<b>Summary</b>	<b>187</b>

---

## INTRODUCTION

Lysosomes are acidic cellular vacuoles that are heterogeneous in shape and size and function in degrading biological constituents derived from the intracellular and extracellular space (Lee and Marzella, 1992; Seglen and Bohley, 1992). In this chapter we will review the mechanisms that regulate the functions of lysosomes and discuss how alterations in these functions lead to cell pathology with special reference to acute and chronic cell injury.

For reviews on the physiology and pathology of biosynthesis, sorting, and processing of lysosomal enzymes and of transport of ions, amino acids, and other macromolecules to lysosomes, readers are referred to the reviews by Kornfeld (1990) and Thoene, (1992).

## LYSOSOMAL DEGRADATION PATHWAYS


### Autophagy and Heterophagy

The lysosomal pathway for degradation of cellular constituents is called autophagy. Autophagy is subdivided into *macroautophagy*, *microautophagy*, and *crinophagy*. *Macroautophagy* is active in nonselective "bulk" degradation of organelles and is activated especially during nutrient deprivation (Mortimore et al., 1989; Seglen et al., 1991; Seglen and Bohley, 1992). *Microautophagy* is an ongoing process for degrading cytosolic constituents in basal conditions (Marzella and Glaumann, 1987; Mortimore et al., 1988). *Crinophagy* participates in degradation of secretory proteins (Marzella and Glaumann, 1987).

Macroautophagic vacuoles are formed by membranes of the endoplasmic reticulum (ER) or Golgi apparatus (Marzella and Glaumann, 1987; Dunn, 1990; Yamamoto et al., 1990a,b; Ueno et al., 1991; Noda and Farquhar, 1992). The earliest structure identifiable by electron microscopy, the autophagosome, is typically bounded by two membranes which segregate intact organelles and cytosolic com-

ponents (Figure 1). The autophagosome fuses with one or several preexisting lysosomes, which contain lysosomal hydrolases. At this stage this structure is called an autophagic vacuole and the degradation of the segregated cytoplasm is carried out. Undegradable substances are in some cases excreted to the extracellular space or more commonly remain stored intracellularly in residual bodies.

Microautophagic vacuoles are autophagic vacuoles forming within a lysosome. They arise by invaginations of surface membranes of lysosomes, leading to the for-




**Figure 1.** Ultrastructural appearance of autophagic vacuoles. **A.** The micrograph shows a newly formed autophagic vacuole from a cultured rat hepatocyte. The vacuole contains several intact cellular constituents, a mitochondrion (M), rough and smooth endoplasmic reticulum cisternae, and cytosol. At this stage, the autophagic vacuole is surrounded by two surface membrane (arrowheads). **B.** The micrograph shows an autophagic vacuole from a rat liver in a later stage of development. Only one surface membrane surrounds the vacuole (arrowheads) and the sequestered mitochondrion (M), and other constituents appear to be undergoing degradation. Magnifications: **A**,  $\times 47,000$ ; **B**,  $\times 58,000$ .

mation of an intralysosomal vesicle. Cytosolic components, such as glycogen, ribosomes, or soluble proteins, seem to be taken up in this fashion (Marzella and Glaumann, 1987).

Crinophagic vacuoles are lysosomes containing secretory proteins undergoing intracellular degradation. Newly synthesized secretory proteins are either secreted constitutively or are packaged into secretory vacuoles for eventual extracellular discharge. In some instances, the secretory vacuoles fuse with the lysosomes and the secretory proteins they contain are degraded intracellularly.

The lysosomal pathway for uptake and degradation of materials from the extracellular space is called heterophagy and is particularly active in macrophages and other phagocytes (Figure 2 A,B). This pathway transports materials, such as microorganisms and cell fragments, from the cell surface to the lysosomes via phagosomes for degradation. Proteins, solutes, and other nutrients are delivered to endosomes via coated pits and vesicles. Internalized constituents, including mem-



**Figure 2.** Ultrastructural appearance of heterophagic vacuoles. **A.** This micrograph shows a resting Kupffer cell from rat liver. Note the presence of numerous lysosomes (L). **B.** This micrograph shows a Kupffer cell from a human liver following shock. Note that the lysosomes (L) are full of amorphous materials and are markedly enlarged. These materials are probably derived from the phagocytosis of cellular debris present in the space of Disse or hepatocyte sinusoid. Magnifications: **A**,  $\times 32,000$ ; **B**,  $\times 16,000$ .

brane, ligands, and receptors, are either recycled to the cell surface or shuttled to lysosomes via late endosomes for eventual degradation.


The lysosomal degradation pathways are shown schematically in Figure 3. This figure also illustrates the functional relationships between the endoplasmic reticulum, Golgi apparatus, and plasma membrane and the lysosomes.

Nonlysosomal degradation pathways are also present in cells. These pathways differ from the lysosomal pathways in subcellular localization, sensitivity to inhibitors, substrate specificity, pH optima, and physiological functions and are regulated independently. For a discussion of the regulation of nonlysosomal degradation pathways and their participation in cell pathology, see Lee and Marzella (1994).

### Degradative Capacity of Lysosomal Enzymes

More than fifty lysosomal enzymes have been identified and have been shown to degrade nearly all biological molecules (proteins, lipids, carbohydrates, and nucleic acids) (de Duve, 1983). Most enzymes are "soluble" or loosely associated with the lysosomal membrane. A few enzymes, such as the membrane-associated form of acid phosphatase, are tightly bound and are considered integral membrane proteins (Himeno et al., 1989). Within the lysosomal matrix, the lysosomal enzymes may exist as aggregates. This property favors the retention of the lysosomal enzymes within the lysosomal matrix. It is not known whether individual lysosomes contain the full range of degradative enzymes or if variable numbers and types of hydrolases are present in each lysosomal organelle. The turnover rate of lysosomal enzymes is relatively rapid (approximately one to two days) (Burnside and Schneider, 1982). The half-life of individual lysosomal enzymes varies from 15 hrs to 3 days (Kominami et al., 1987).

Proteins are degraded to the level of constituent amino acids through sequential attack by a variety of lysosomal proteases (see below). The hydrolysis of lipids also takes place in the lysosomal compartment by the action of acid lipases to yield glycerols and fatty acids. Glycolipids, sphingomyelins, and phospholipids are all degraded in lysosomes. The degradation of glycogen can occur in lysosomes by acid  $\alpha$ -glucosidases. The degradation of carbohydrate moieties in sugars, proteins, and lipids proceeds by the action of exoenzymes (e.g., glycosidases) giving monosaccharides. In the case of glycoproteins, the peptide backbone is degraded by various lysosomal proteases, followed by the breakdown of glycans. Nucleic acids are first hydrolyzed by an endonuclease, either acid deoxyribonuclease or ribonuclease, into oligonucleotides. Then the oligonucleotides are cleaved by an acid exonuclease to release 3'-phosphomononucleotides and subsequently nucleosides and inorganic phosphates. Breakdown products of lysosomal degradation (amino acids, fatty acids, glycerol, monoacylglycerols, cholesterol, and sugars) return to the cytosol by diffusion/permeation or are transported out of the lysosome by newly discovered specific carriers systems. At least 14 systems active in the transport of



**Figure 3.** Overview of autophagy and heterophagy. Autophagy: cytoplasmic organelles are sequestered into macroautophagic vacuoles (AV). Proteins and other cytosolic constituents are taken up in microautophagic vacuoles (av). Secretory products diverted from the secretory pathway are taken up in crinophagic vacuoles (C). Macroautophagic and crinophagic vacuoles acquire digestive enzymes by fusing with lysosomes. As the vacuolar contents are degraded, the lysosomes (L) diminish in size, become electron-dense and are designated dense bodies (DB). Lysosomes containing undegradable residues such as lipofuscin, are designated residual bodies (RB), which may in some instances be extruded from cells. Heterophagy: extracellular constituents are carried via phagosomes (P) to the lysosomes for degradation. Proteins and solutes are transported to “early” endosomes ( $E_1$ ) via coated pits (CP) and vesicles (CV) or pinosomes. Membranes and internalized constituents are recycled to the plasma membrane (PM) or are transported to the lysosomes via “late” endosomes ( $E_2$ ). The transport of newly synthesized lysosomal enzymes to lysosomes follows the cytosol-rough endoplasmic reticulum (RER)-smooth endoplasmic reticulum (SER)-Golgi apparatus pathway taken by secretory proteins. In the trans-Golgi network (TGN), the lysosomal enzymes are sorted out from proteins destined for secretion and are transported to the lysosomes via late endosomes ( $E_2$ ).

inorganic ions, amino acids, and other metabolites have been characterized. The specific transport proteins have not yet been identified (Thoene, 1992).

## REGULATION OF LYSOSOMAL PROTEIN DEGRADATION

### Enzyme Activity, Acidification

Several physiological conditions, such as growth or regeneration, can up-regulate the activity of lysosomal enzymes by increasing their absolute concentration or their catalytic activity (de Groen et al., 1989; Rhodes et al., 1989). Changes in levels of naturally occurring enzyme inhibitors may also play a role (Barrett, 1987). Lysosomal acidification mediated by H<sup>+</sup>-ATPase (pH close to 5) is essential to activate lysosomal enzymes. The proton gradient across the lysosomal membrane may also contribute to the transport of products of lysosomal hydrolysis to the cytosol (Ohkuma, 1987). Vacuolar acidification is critical for processing lysosomal proenzymes to mature hydrolases and for sorting them (Rothman et al., 1989).

The generation of a pH gradient in the lysosomes is almost exclusively due to an electrogenic proton pump driven by a H<sup>+</sup>-ATPase in the lysosomal membrane (Schneider, 1987; Rodman et al., 1991). The H<sup>+</sup>-ATPase is made up of eight or nine subunits. A 72-kDa subunit is the catalytic site for ATP hydrolysis, a 57 kDa subunit is a regulatory nucleotide-binding protein, and a 17-kDa subunit most likely participates in forming the proton channel (Klionsky et al., 1990).

### Amino Acids and Hormones

Lysosomal protein degradation is regulated by amino acid levels in conjunction with the synergistic and additive effects of hormones. At normal plasma levels of amino acids, cellular proteolytic responses to hormones are commensurate with those caused by amino acid deprivation. The most important hormone to stimulate hepatic macroautophagy and lysosomal protein degradation is glucagon (Mortimore and Pösö, 1987; Mortimore et al., 1989). In skeletal muscle, increased catecholamine levels have been linked to stimulation of protein degradation (Nie et al., 1989). Epinephrine has also been shown to stimulate lysosomal protein degradation in the liver (Mortimore and Pösö, 1987). In muscle, workload is an important regulator of muscle mass.

Insulin and other growth-promoting factors inhibit lysosomal proteolysis (Ballard and Gunn, 1982). It has been found that glucocorticoids stimulate lysosomal protein degradation in hepatocytes (Hopgood et al., 1981). Estrogen can inhibit osteoclastic resorption activity by down-regulation of lysosomal gene expression (Oursler et al., 1993). The inhibitory influence of serum on protein degradation in cultured cells is also presumed to be mediated by growth factors and hormones in



the serum. Serum deprivation causes only a transient increase in proteolysis. After 24 hours, the rates of protein degradation decline to levels equal to or even lower than controls. A diet deficient in protein reduces the lysosomal degradation of protein in muscle (Tawa et al., 1992).

### **Effects of Growth, Age, pH, and Calcium levels of Cells**

The growth state of cells is important in the modulation of intracellular protein degradation (Ballard, 1987; Papadopoulos and Pfeifer, 1987). The stimulation of cytoplasmic growth seen during cellular proliferation (e.g., adrenocorticotropic hormone-stimulated proliferation of adrenal zona fasciculata) or hypertrophy (e.g., contralateral compensatory hypertrophy after unilateral nephrectomy) suppresses autophagic-lysosomal degradation (Müller et al., 1987; Jurilj and Pfeifer, 1990).

Cell age also influences intracellular protein degradation (Ballard, 1987; Dice, 1989). It has been proposed that decreased proteolysis may be responsible for the appreciable accumulation of posttranslationally altered proteins in senescent cells. The proliferative arrest in senescent cells may be due to a defect in certain proteolytic systems, and deficient degradation of oxidized proteins has been demonstrated in aging cells (Oliver et al., 1987).

A rise in intracellular pH causes a marked decrease in protein degradation and an increase in protein synthesis (Fuller et al., 1989). Increases in cytosolic  $\text{Ca}^{2+}$  levels also accelerate proteolysis in muscles by lysosomal and nonlysosomal pathways (Zeman et al., 1985). It has been proposed that a calcium transport system in the lysosomal membrane functions in regulating lysosomal protein degradation (Lemons and Thoene, 1991).

## **FUNCTIONS OF LYSOSOMAL ENZYMES**

### **Degradation of Proteins**

The degradation of proteins by lysosomes is accomplished by exoenzymes (exopeptidases) that cleave bonds only near the ends of molecular chains and by endoenzymes (endopeptidases or proteinases) that hydrolyze peptide bonds in the middle of molecular chains. Endopeptidases are subdivided into cysteine proteinases (e.g., cathepsin B, H, and L) and aspartic proteinases (e.g., cathepsin D and E) (Kirsche and Barret, 1987) based on the identity of the catalytic group at the active site. The degradation of proteins by lysosomal enzymes is essential for several cell function.

As a rule, lysosomal proteases, completely degrade the intracellular proteins segregated in the lysosomes and play an important role in the turnover of cellular proteins. The lysosomal proteases are also involved in changing cellular phenotype by degrading certain differentiation-related proteins (Teichert et al., 1989), and al-

terations in levels and/or activity of lysosomal enzymes occur during cell differentiation. A number of secretory proteins are degraded by lysosomal proteases (Willemer et al., 1990). Examples are hormones, such as insulin (Schnell et al., 1988), prolactin (Kuriakose, et al., 1989), parathormone (Pillai and Zull, 1986), corticotropin, melanotropin (Uchiyama et al., 1990), and catecholamines (Weiler et al., 1990). Partial proteolytic processing of certain proteins occurs in prelysosomal organelles (for a review, see Lee and Marzella, 1992). Examples of processing of secretory proteins by lysosomal proteases are the conversion of thyroglobulin to thyroxine (Rousset et al., 1989a,b; Rousset and Mornex, 1991), the conversion of prorenin to renin (Wang et al., 1991), and the conversion of procollagen to collagen (Helseth and Veis, 1984). In antigen-presenting cells, lysosomal proteases process endocytosed protein antigens and generate antigen-MHC II complex which are then translocated to the cell surface for presentation to T cells.

Lysosomal proteases also degrade extracellular proteins intracellularly following endocytic uptake (Del Rosso et al., 1991) or extracellularly following the secretion of lysosomal enzymes (Ishii et al., 1991). By these mechanisms, lysosomal proteases participate in remodeling extracellular matrix and bone and in the degradation of plasma proteins, lipoproteins, and cells with finite life spans. Cathepsin B and L, for example, appear indispensable in bone resorption by degrading collagen in the bone matrix (Delaissé et al., 1991). Examples of extracellular proteins that are substrates for lysosomal enzymes are albumin (Baricos et al., 1987), the urokinase type of plasminogen activator (Buktenica et al., 1987; Jensen et al., 1990), low density lipoprotein (Brown and Goldstein, 1986), renin (Marks et al., 1991), and hemoglobin (Diment and Stahl, 1985).

In organs, such as the liver and kidney, lysosomal degradation of endocytosed or phagocytosed constituents assumes a specific physiological importance. For example, in the liver, the resident macrophages (Kupffer cells) clear from the portal circulation bacteria and endotoxin derived from the gastrointestinal tract (Ulevitch, 1991). In the renal tubular epithelial cells, the proteins filtered from glomeruli are rapidly reabsorbed via endocytosis. The internalized proteins begin to undergo degradation in the endosomes and are transported to lysosomes, where protein degradation is completed (Andersen et al., 1987; Haga, 1989). The endocytosis and degradation of filtered protein is greatly augmented when the glomerular filtration barrier is damaged (Haga, 1989). In these conditions, the number and volume of lysosomes increases markedly and acid hydrolases are greatly activated.

### **Degradation of Lipoproteins and Membrane Lipids**

The degradation of phospholipids and neutral lipids segregated in lysosomes by uptake of cellular membranes and lipoprotein particles is accomplished by lysosomal acid lipases (Warner et al., 1981). A lysosomal lipase with broad substrate specificity is almost exclusively responsible for the lysosomal hydrolysis of cholesterol esters, triglycerols, and diacylglycerols. Lysosomes also contain

phospholipase A (Löffler and Kunze, 1987; Bartolf and Franson, 1990). Several factors effectively mitigate against cell injury caused by the unregulated hydrolysis of membrane diacylphospholipids by this enzyme and prevent the loss of membrane integrity in normal cells. These factors include the lack of optimal pH in the cytosol, the presence of cations, such as  $Mg^{2+}$ ,  $Ca^{2+}$ ,  $Na^+$ , and  $K^+$ , and of intracellular and extracellular proteins, such as histone, albumin, fatty acid binding proteins, and immunoglobulins, which inhibit enzyme activity (Kunze et al., 1988). A lysosomal phospholipase C converts phospholipids into diglycerides (Matsuzawa and Hostetler, 1980). Lysosomal phospholipase C also plays a role in the degradation of membranes subjected to lipid peroxidation in injured cells.

## LYSOSOMES IN ACUTE AND CHRONIC CELL INJURY

### Intracellular Leakage of Lysosomal Enzymes

The lysosomal membrane provides a physical barrier separating the degradative activity of lysosomal hydrolases from cytoplasm. Impairment of lysosomal membrane integrity and release of hydrolases to the cytosol are severely detrimental to cellular physiological functions and integrity. The stability of the lysosomal membrane can be impaired by free radicals probably through lipid peroxidation reactions. It has been demonstrated that loss of lysosomal membrane integrity by lipid peroxidation occurs in photooxidation-induced cell injury (Olsson et al., 1989). Leakage of lysosomal enzymes also occurs after cell death and contributes to autolysis and necrosis.

Several naturally occurring enzyme inhibitors protect living cells against injury caused by the release of lysosomal enzymes (Barrett, 1987; Kirschke and Barrett, 1987). Examples are  $\alpha_2$ -macroglobulin,  $\alpha$ -cysteine proteinase inhibitor, and cystatins. The first two inhibitors are found in plasma whereas the latter is found in cells and body fluids (Kirschke and Barrett, 1987; Aoyagi, 1989). The cystatins are a group of low molecular weight inhibitors classified on the basis of the type of cell in which they are found. Cystatin A is present in epithelial cells and leukocytes. Cystatin B is in lymphocytes and monocytes. Cystatin C is in neuroendocrine cells. Finally cystatin S is in salivary glands.

### Extracellular Release of Lysosomal Enzymes

Lysosomal enzymes released from neutrophils, macrophages, and other inflammatory cells degrade critical extracellular proteins and may induce injury and loss of function in various organ systems (Kesava Reddy and Dhar, 1991). For example, increased activities of cathepsin B and L play a role in the degradation of cartilage collagens in arthritis (Maciewicz and Wotton, 1991). It has been proposed

that one of the factors responsible for the development of smoking-related emphysema is an imbalance between proteases (e.g., elastase) and their inhibitors ( $\alpha$ -1 antitrypsin), resulting in the destruction of lung parenchyma and interstitium (Snider et al., 1991). Cysteine proteinases are the most likely source of the potent contact-dependent elastase activity of macrophages (Chapman et al., 1984). Cathepsin L has drawn considerable attention in this regard (Reilly et al., 1989).

Highly purified cysteine proteinases B and L are also able to degrade glomerular basement membrane (GBM) and isolated GBM constituents (Thomas and Davies, 1989; Baricos et al., 1991). In experimental models of glomerular disease, the administration of cysteine proteinase inhibitors decreases proteinuria (Baricos et al., 1991). Lysosomal aspartic and cysteine proteinases play a role in the degradation of filtered protein that is endocytosed by proximal tubular cells (Olbricht et al., 1987; Baricos and Shah, 1989).

Rheumatoid arthritis is a systemic inflammatory process of unknown etiology in which the destruction of articular connective tissue occurs. Increased levels of cathepsin L and *ras* oncogene transcripts are detectable predominantly in synovial cells in the vicinity of sites of active joint destruction (Trabandt et al., 1990). Cathepsin L is a major *ras*-induced proteinase. *Ras*-induced proteinases have been implicated in the degradation of basement membrane that leads to the ingress and the pathognomonic accumulation of T cells in synovium in rheumatoid arthritis (Gay and Koopman, 1989; Ziff, 1989).

### Free Radical Injury

Intracellular ferric iron is an essential mediator of membrane damage caused by free radicals and other reactive oxygen species. A cell pool of ferric iron is reduced by superoxide anions to ferrous iron at first. Ferrous iron in turn reduces  $H_2O_2$  to hydroxyl free radicals. The degradation of iron-containing proteins by lysosomal proteases is an important source of free iron that is available for lipid peroxidation. Ferritin is segregated in the lysosomes by autophagy. The protein moiety is degraded, albeit slowly, by lysosomal cathepsins (Glaumann and Marzella, 1981) and iron is released due to the acidic pH (Sakaida et al., 1990; Hoffman et al., 1991). Modulation of autophagic protein degradation influences the size of the iron pool and the susceptibility of deferoxamine-treated hepatocytes to injury by *t*-butyl hydroperoxide (Sakaida et al., 1990).

### Intracellular Activation of Zymogen Enzymes by Crinophagy

Intracellular degradation of secretory proteins by lysosomes can occur by crinophagy (Marzella and Glaumann, 1987). In the pancreatic acinar cell crinophagy may lead to intracellular activation of zymogen enzymes and to pancreatic injury (Resau et al., 1984). Serine proteases (e.g., trypsinogen) are probably activated inside the pancreatic parenchyma by lysosomal hydrolases (e.g., cathepsins), and

autodigestion of pancreatic parenchyma occurs (Steer and Meldolesi, 1987; Willemer and Alder, 1991).

### Cytotoxic Drugs

Many cytotoxic drugs induce alterations in lysosomes. It has been proposed that these alterations can further increase cell injury, although in many instances direct evidence of the mechanisms involved is lacking.

Aminoglycosides, such as gentamicin, are taken up by receptor-mediated endocytosis and accumulate in lysosomes of renal proximal tubular cells (Wedeen et al., 1983). Although the pathogenesis of the nephrotoxicity remains unknown, it has been proposed that changes in the physiological functions of lysosomes induced by aminoglycosides may alter cellular metabolism and ultimately cause cell death (Kaloyanides and Pastoriza, 1980). Gentamicin can reduce cathepsin B and L activities in renal tubular cells within 24h after inoculation by inhibiting enzyme activities and decreasing enzyme biosynthesis.

Another example of a nephrotoxic drug that induces marked alteration of lysosomes is the immunosuppressive drug cyclosporine (Palestine et al., 1986). This drug may decrease renal blood flow and induce toxic glomerulopathy, tubular atrophy, interstitial fibrosis, and arteriolopathy (Palestine et al., 1986). Kidneys of rats treated with toxic doses of cyclosporine contain numerous lysosomes, autophagic vacuoles, and myeloid bodies (Whiting et al., 1982). It is not clear if these alterations are simply the result of, or if they also contribute to cell injury.

### Acidotropic Agents

The so-called acidotropic or lysosomotropic agents cause swelling of lysosomes by dissipating the  $H^+$  gradient and inhibiting lysosomal protein degradation. These agents are weak bases, such as products of cellular metabolism (ammonia,  $NH_4Cl$ ), or drugs such as chloroquine. They freely permeate into cells and subcellular organelles. Within acidic compartments, such as lysosomes, the bases are protonated and become trapped. The consumption of protons by the weak bases elevates the intralysosomal pH and decreases the catalytic activities of lysosomal enzymes (Krogstad and Schlesinger, 1987). The accumulation of protonated weak bases in the lysosomes is accompanied by an influx of water, leading to marked enlargement of lysosomes and cellular vacuolation (Kalina and Socher, 1991). In the case of inhibitors, such as the weak base chloroquine, lysosomal degradation is also impaired by direct inhibition of cathepsins and by inhibition of mannose-6-phosphate receptor (MPR) recycling, which causes enhanced secretion of lysosomal enzymes (Geuze et al., 1985; Brown et al., 1986). Quaternary ammonium compounds may also inhibit the activities of lysosomal enzymes by direct interaction with lysosomal proteases (Matsumoto et al., 1989).

## Infections, Sepsis

Protein degradation in skeletal muscle is commonly augmented by fever and sepsis (see a review by Palmer, 1990). Sepsis markedly enhances (up to 50%) the degradation of muscle protein (Hasselgren et al., 1986) and alters the response of muscle protein turnover to the regulatory amino acid leucine.

The lysosomes of phagocytes are important in infections because they function as an antimicrobial defense system. The oxidative burst and oxygen-independent mechanisms, such as cationic and other nonenzymatic proteins, constitute the first line of defense against microorganisms. The acid proteases are a secondary defense mechanism and are responsible for degrading endocytosed pathogens (Yu and Marzella, 1990). The ability of some microbial pathogens to escape degradation by the lysosomes leads to disease. The mechanisms responsible for the failure of lysosomes to kill pathogens are (1) escape of microorganisms from endocytic compartments; (2) failure of fusion between phagosomes and lysosomes; (3) loss of capacity to degrade microorganisms; and (4) deficient lysosomal acidification.

### *Endocytosis of Microorganisms*

Viruses use two routes to gain entry into cells. The first route of entry is nonspecific. Viruses penetrate the cell by direct fusion of the viral envelope with the cell surface membrane (Payne et al., 1990; Wittels and Spear, 1990). The second route of entry is via receptor-mediated endocytosis (RME) (Pauza and Price, 1988). The acidification machinery is triggered immediately after the formation of early endosomes, and the H<sup>+</sup>-ATPase is activated. At an acidic pH, the internalized viral envelope fuses with the endosomal membrane and releases the nucleocapsid into the cytoplasm before the endosome merges with a lysosome. Viruses thereby evade degradation by lysosomes (Pauza and Price, 1988). This event is observable in many viruses, such as orthomyxoviruses, togaviruses, Semliki forest, vesicular stomatitis, influenza, and retroviruses (Yu and Marzella, 1990). The fusion between viral and endosomal membranes is pH-dependent and can be inhibited by weak bases.

Phagocytosis is a major route for the uptake of microorganisms (e.g., bacteria, fungi, or protozoans) in lysosomes. Some microorganisms, such as *Rickettsia* and *Trypanosomes*, can escape from phagosomes and survive within the cytoplasm (Weiss, 1982). In *Trypanosoma cruzi* infection, a protozoan-derived neuraminidase plays an important role in enhancing parasite access to the cytoplasm of host cells by removing terminal sialyl moieties on carbohydrate chains of lysosomal membrane glycoproteins (Fenton-Hall et al., 1992). In addition, the fusion of lysosomes with the parasitophorous vacuole seems to be required to facilitate the entry of *T. cruzi* into host cytoplasm (Tardieux et al., 1992).

### ***Fusion between Phagosomes and Lysosomes***

In cultured macrophages or monocytes lysosomes are unable to fuse with phagosomes containing certain types of pathogenetic microorganisms. These microorganisms include *Legionella pneumophila*, *Mycobacterium tuberculosis*, and *Leishmania braziliensis* (Lee and Marzella, 1994). Polyanions, such as those present in some microorganisms and the endogenously produced weak base ammonia, can block phagosome-lysosome fusion. Of interest, only viable microorganisms can suppress fusion between lysosomes and phagosomes. Microorganisms that are nonviable or inactivated intracellularly lose this ability (Krogstad and Schlesinger, 1987).

### ***Activity of Lysosomal Enzymes***

Several microorganisms remain viable after reaching the lysosomes and a few even continue to replicate. Examples of these resistant pathogens are *Histoplasma capsulatum*, *Salmonella typhimurium*, and *Leishmania* spp. (Lee and Marzella, 1994). Mechanisms for the resistance to degradation of some of these microorganisms are inhibition of biosynthesis of lysosomal hydrolases (Chakraborty and Das, 1989), protection by carbohydrate moieties of surface glycoproteins, and release of excretory factors that inhibit lysosomal enzyme activity. It is noteworthy that the expression and secretion of cysteine proteinase aids some protozoa in degrading and invading host tissue. This mechanism accounts for the cytopathic effect of virulent trophozoites of *Entamoeba histolytica* (Keene et al., 1990).

### ***Acidification of Phagosomes***

Another mechanism that accounts for the survival of some microorganisms in lysosomal compartments of host cells is inhibition of lysosomal or phagosomal acidification (Sibley et al., 1985; Black et al., 1986). Microorganisms able to inhibit acidification include *Toxoplasma gondii*, *Legionella pneumophila*, *Nocardia asteroides*, and *Mycobacterium tuberculosis*.

Elevation of intralysosomal pH can arrest growth and proliferation of microorganisms (Krogstad and Schlesinger, 1987). A classic case is seen after the application of the antimalarial drug chloroquine or the weak base  $\text{NH}_4\text{Cl}$  to *Plasmodium falciparum*. These compounds raise the pH of the food vacuoles (lysosomes) of *Plasmodium falciparum* and suppress the degradation of hemoglobin that is indispensable for normal development and replication of the parasite (Krogstad and Schlesinger, 1987; Rosenthal et al., 1988).

## **Burn Injury**

Burn injury increases protein degradation in skeletal muscle up to twofold by the second day after injury (Odessey, 1987). The induction of lysosomal enzyme synthesis may enhance proteolysis in burn injury (Odessey, 1987).

### Myopathies and Denervation Injuries

In several pathological conditions, protein degradation is enhanced in skeletal muscle. Myofibrillar components are particularly affected, and pronounced muscle atrophy results. Several proteolytic systems appear to participate in the development of muscular atrophy (Fagan et al., 1987; Katunuma and Kominami, 1987; Driscoll and Goldberg, 1989). It has been proposed that both lysosomal cathepsins and  $\text{Ca}^{2+}$ -dependent proteases play a role in the enhanced protein degradation found in dystrophic (Turner et al., 1988) or injured (Furuno and Goldberg, 1986) muscle.

In the case of muscle atrophy induced by denervation, an increase in autophagic lysosomal proteolysis may be partially responsible for the atrophy because the activity of lysosomal proteases is augmented (Bird and Roisen, 1986). It is also proposed that  $\text{Ca}^{2+}$ -dependent neutral proteases (CANPs) mediate muscle atrophy in denervation and other conditions (Bond and Bulter, 1987; Hussain et al., 1987; Badalamente et al., 1989). At least three degradative pathways are active in denervated muscle. These are a non lysosomal pathway in basal conditions, a  $\text{Ca}^{2+}$ -dependent pathway activated during increased muscle tension (Baracos and Goldberg, 1986), and an autophagic-lysosomal pathway active during metabolic stress (Furuno et al., 1990).

### Starvation and Stress

In the postabsorptive state, lysosomal protein degradation in the liver is essential to maintain amino acids and glucose levels in the bloodstream (Mortimore and Khurana, 1990). In stress responses, increased amounts of amino acids are made available through protein degradation to sustain metabolism and the synthesis of new proteins involved in cellular adaptive responses. During short-term starvation, hepatocytes are the most important endogenous source of amino acids. Beyond 48h of starvation, the degradation of nonrespiratory skeletal muscle is accelerated, and the amount of protein in muscle decreases (Mortimore and Pösö, 1987). Most if not all accelerated protein degradation occurs in the lysosomes.

Exercise of high intensity and long duration markedly intensifies protein degradation in the liver (Dohm et al., 1987) and in skeletal muscle (Parkhouse, 1988). Myofibrillary proteins are not affected. The degradation of these contractile proteins is actually diminished during exercise (Dohm et al., 1987; Kasperek and Snider, 1989). This has been explained by an elevation of intralysosomal pH through accumulation of ammonia after exercise and an increase in the permeability of lysosomal membranes (Tsuboi et al., 1993).

### Accumulation of Iron and Other Metals in Lysosomes

Idiopathic hemochromatosis is a hereditary metabolic disease in which excessive iron accumulates within the parenchyma of many organs, particularly the



liver. The intracellular iron is bound to apoferritin to form ferritin molecules, which are located in the cytosol. Ferritin also accumulates in lysosomes because of its relative resistance to degradation (Glaumann and Marzella, 1981). Although the pathogenesis of cell injury in idiopathic hemochromatosis has not been completely elucidated, it is postulated that the generation of free radicals and peroxidation of membrane lipid play an important role (Myers et al., 1991). Ultrastructural alterations of lysosomes occur in iron-overloaded cells in parallel with biochemical evidence of increased lysosomal fragility and leakage of acid hydrolases (LeSage et al., 1986). Lysosomes isolated from iron-overloaded livers appear enlarged and deformed and show an increase in membrane fragility, a decrease in membrane fluidity, and an rise in pH (Myers et al., 1991). Increased lysosomal membrane fragility is also observed in iron-loaded, cultured, cardiac myocytes (Link et al., 1993).

Untreated patients with hemochromatosis usually develop liver cirrhosis (Basset et al., 1986). Stål et al. (1990) found that in biopsies from livers with precirrhotic hemochromatosis, the volume density ( $V_d$ ) of lysosomes increased in hepatocytes and Kupffer cells in parallel with increases in iron. The number of iron-laden lysosomes dramatically decreases and hepatic ultrastructure reverts to normal after therapeutic phlebotomies (Cleton et al., 1988; Stål et al., 1990).

The accumulation of other mineral elements in the lysosomes may also damage the lysosomal membrane and lead to cell injury. For example, lysosomal damage is closely correlated with the amount and duration of aluminum loading (Stein et al., 1987; Berry et al., 1988).

Mineral elements, such as aluminum, chromium, uranium, and cerium are reabsorbed by renal epithelial cells in the proximal convoluted tubules and are precipitated in lysosomes as insoluble phosphate salts by the action of acid phosphatase. Eventually, these phosphate salts are excreted in the urine. Pulmonary cells dispose of metal particles inhaled into the respiratory passages by precipitation within lysosomes. The accumulation of phosphate particles in the lysosomes of pneumocytes prevents the diffusion of these toxins into the interstitial capillaries. These metal salts and other inert inhaled particles are finally slowly cleared by pulmonary macrophages. Some metals can inhibit the activity of lysosomal enzymes. For example,  $\text{Cu}^{2+}$  inhibits lysosomal acid cholesterol ester hydrolase in the presence of hydroxylamine and ascorbic acid (Tanaka et al., 1988). Moreover, the breakdown of metalloprotein may be markedly decreased through inhibition of cathepsin B and/or L activity by protein-associated metal elements (Choudhuri et al., 1992).

### Accumulation of Pigments in Lysosomes

Tissue necrosis, vitamin E deficiency, certain lysosomal storage diseases in the central nervous system, and ageing are associated with the accumulation of lipopigments, called ceroid and lipofuscin, in the lysosomes (Goebel and Busch, 1990;

Palmer et al., 1990). Ceroid is considered to be the undegraded remnant of material derived from heterophagocytosis and is characteristically seen in macrophages (Gedigk and Totovic, 1983). Lipofuscin, on the other hand, is thought to be made up of residues derived from autophagy. These polymerized lipid-protein complexes are resistant to hydrolysis and accumulate in the lysosomes.

Proteolytic decline and peroxidative stress may also contribute to the genesis of lipofuscin (Porta, 1991). In human senescent brains and in brains of patients with Alzheimer's disease, a defective or deficient degradation of a variety of proteins, such as amyloid precursor protein, by lysosomal enzymes plays an important role in the generation of  $\beta$ -amyloid deposits found, for example, within neuritic (senile) plaques (Cras et al., 1991; Tagawa et al., 1992).

### **Storage Diseases**

Lysosomal storage diseases share the following characteristics: a complete or partial deficiency of lysosomal enzymes, an accumulation of undegraded materials within the lysosomes, and inheritance. Several genetic or induced abnormalities and deficiencies of lysosomal hydrolases or cofactors result in the accumulation of undegraded substrate in the lysosomes. The number and size of the lysosomes gradually increases in the affected cells, and the cells and organs become enlarged and dysfunctional (Patel, 1989).

#### ***Inherited***

Several pathophysiological mechanisms induce these genetic storage disorders. The first mechanism is a lack of a protective glycoprotein that normally links certain lysosomal enzymes. This linkage reduces the susceptibility of the enzymes to proteolysis and is necessary for their activities (d'Azzo et al., 1989; Galjart et al., 1990). The second mechanism that induces storage disorders is a deficiency of nonspecific activator proteins (saponins A, B, C, or D) required for the lysosomal enzymatic hydrolysis of glycolipids (sphingolipids) (Li et al., 1988; O'Brien et al., 1988; Sandhoff et al., 1989). In their absence, despite normal lysosomal hydrolase activity, activator-deficient metachromatic leukodystrophy develops.

The third mechanism that induces inherited storage disorders is decreased levels or total deficiency of specific hydrolases caused by (i) decreased or defective biosynthesis due to genetic mutations resulting in amino acid substitution and/or deletion (e.g., Gaucher disease) (Galjaard and Reuser, 1984); (ii) incorrect sorting and targeting of hydrolases (e.g., I-cell disease) (Kornfeld and Mellman, 1989; Kornfeld, 1990); and (iii) defective synthesis of subunits which prevents the normal assembly or translocation of the enzymes (Lau and Neufeld, 1989; Paw et al., 1990). Finally, the fourth mechanism that induces inherited storage disorders is impaired carrier-mediated transport of degradation products from lysosomes (e.g., cystino-

sis; infantile free sialic acid storage disease, and vitamin B<sub>12</sub> storage disorder) (Shih et al., 1989; Tietze et al., 1989; Mancini et al., 1991).

### **Acquired**

Lysosomal storage diseases are inducible by cationic amphiphilic drugs. These compounds cause the formation of lamellar structures containing polar lipids in lysosomes. The mechanisms for the accumulation of lamellar structures include formation of undegradable drug-lipid complexes, raised lysosomal pH induced by the segregated drugs, and reversible inhibition of the activities of lysosomal phospholipases A and C (Reasor, 1989). Numerous reports have indicated that cell injury induced by these cationic drugs parallels the appearance of lamellar structures in cells.

### **Atherosclerosis**

Lysosomes participate in both physiological and pathological lipid metabolism. The stepwise buildup of free cholesterol in lysosomes of vascular smooth muscle cells and macrophages (Tangirala et al., 1993) has been proposed as one of the mechanisms responsible for atherosclerotic plaques.

The biosynthesis of cholesterol is modulated by receptor-mediated endocytosis and lysosomal degradation of low density lipoproteins (LDL) (Brown and Goldstein, 1986). In lysosomes, the protein/phospholipid coat of LDL is degraded and cholesteryl esters are hydrolyzed by lysosomal lipases freeing cholesterol (Brown and Goldstein, 1986). A rise in unesterified cholesterol derived from LDL or from endogenously synthesized cholesterol results in inhibiting cholesterol biosynthesis and activation of a cholesterol-esterification-catalyzing enzyme.

Perturbations in the endocytosis or degradation of LDL derived from the bloodstream or in the esterification of cellular cholesterol by microsomal ACAT can lead to the accumulation of lipids in cells (Tabas et al., 1987). In atherosclerosis, the arterial intima is infiltrated with pathognomonic, lipid-laden cells (so-called foam cells), derived from circulating monocytes or smooth muscle cells of the arterial media. In the early stages, a lipid of foam cells is predominantly localized in intracellular cytosolic inclusions. With the progression of the disease, intracellular lipid deposits become massive and the site of accumulation shifts to the lysosomes (Jerome and Lewis, 1985; Jerome et al., 1991).

LDLs modified by acetylation, oxidation, or conjugation with malondialdehyde are more effective in inducing the formation of lipid-laden (foam) cells. Unlike acetylated LDL, roughly only 50% of internalized oxidized LDL is ultimately degraded. This phenomenon has been ascribed to resistance of oxidized LDL to degradation by lysosomal cathepsins (Loughheed et al., 1991).

Reverse transport of cholesterol from lysosomes to plasma membrane is known to take place. This efflux is constitutive. High density lipoprotein particles (HDL) remove the free cholesterol from the plasma membrane of cells. A negative correla-

tion exists between plasma HDL levels and atherosclerosis indicating the crucial role of cholesterol efflux from lysosomes in the pathogenesis of this disease.

## **LYSOSOMAL DEGRADATION IN TUMORIGENESIS AND TUMOR METASTASIS**

### **Lysosomal Protein Degradation and Acidification in Cancer Cells**

Normal cells respond to a variety of stressful stimuli, such as nutritional deprivation by increasing protein degradation. It has been hypothesized that cancer cells may be resistant to stimuli that accelerate protein degradation and may also down-regulate basal proteolysis. These changes could enhance the survival and growth of the cancer cells particularly in conditions of nutrient stress (Lee et al., 1989 and 1992). It is generally accepted that cancer cells manifest lower basal protein degradation and decreased lysosomal enzyme activities, compared with normal cells (Schwarze and Seglen, 1985).

The viability of normal hepatocytes incubated in nutrient-free media increases to the same level as that of transformed hepatocytes when an autophagic inhibitor, 3-methyladenine, is added to culture media (Schwarze and Seglen, 1985). These observations support the postulation that the capacity to down-regulate autophagic protein degradation increases the resistance to injury and enhances the growth of cancer cells.

### **Role of Lysosomal Proteases in Tumor Invasion and Metastasis**

Unlike normal parenchymal cells (Hohman and Bowers, 1984), cancer cells secrete a variety of proteases that degrade extracellular matrix and facilitate local invasion and metastasis of tumors (Boyer and Tannock, 1993). These proteases include urokinase and tissue type plasminogen activators (Rifkin et al., 1989; Hollas et al., 1991; Oka et al., 1991), collagenases (Nakajima et al., 1987), trypsin (Koi-vunen et al., 1991), metalloprotease (gelatinase) (Matrisian, 1990; Chen et al., 1991), glycosidase (Nakajima et al., 1984), stromelysin (Matrisian, 1990), and the lysosomal cysteine or aspartate proteases (Nathalie et al., 1990), B (Watanabe et al., 1987), D (Capony et al., 1989; Rochefort et al., 1990), H (Tsushima et al., 1991), and L (Dong et al., 1989).

The balance between the levels of lysosomal and nonlysosomal proteases and levels of their inhibitors, altered synthesis and translocation of cathepsin B, and in particular an enhanced secretion of enzyme are critical determinants of tumor growth and invasion. Sloane et al. (1990) have proposed that malignant tumor cells are capable of establishing an acidic extracellular microenvironment, in which a variety of lysosomal proteases (e.g., cathepsin B) and glycosidases (e.g.,  $\beta$ -hexosaminidase) function optimally. By this mechanism, the

destruction of basement membrane and connective tissues matrices may thus be intensified.

### ***Cathepsin B***

Secretion of the cysteine proteinase cathepsin B by malignant and benign tumors has drawn a great deal of attention because secretion of cathepsin correlates with the metastatic potential of tumors (Keren and LeGrue, 1988). Cathepsin B activity is regulated by an intracellular cysteine proteinase inhibitor (CPI), also known as cystatin. In many tumors the regulation of protease activity by cysteine proteinase inhibitors is lessened because of decreases in the levels of CPI or in the affinity of CPI for cysteine proteases (Lah et al., 1989).

### ***Cathepsin L***

Secretion of procathepsin L, a lysosomal cysteine protease precursor, is markedly up-regulated by tumor promoters (Gal et al., 1985), growth factors (e.g., epidermal growth factor [EGF]; fibroblast growth factor [FGF]; platelet-derived growth factor [PDGF]) (Frick et al., 1985; Chiang and Nilsen-Hamilton, 1986; Dong et al., 1989), and viral transformation (Hiwasa et al., 1991). The level of expression of cathepsin L in *H-ras*-transformed murine fibroblasts is closely associated with their metastatic potential of the cells (Denhardt et al., 1987).

### ***Cathepsin D***

Several lines of evidence have indicated the importance of up-regulated biosynthesis and increased secretion of cathepsin D in enhancing tumor proliferation, invasion, and metastasis (Rochefort et al., 1990). For example, the forms of cathepsin D secreted by cancer cells may have autocrine mitogenic potential (Vignon et al., 1986; Garcia et al., 1990). Also critical in tumorigenesis is the role of procathepsin D in degrading or activating specific substrates. Indeed, this secreted enzyme has been shown to be able to degrade basement membranes, impair growth factor receptors, modulate antigen processing, activate cathepsin B and other proteases, and activate transforming growth factor- $\beta$  (TGF  $\beta$ ) (Briozzo et al., 1988; Pagano et al., 1989; Rochefort et al., 1990).

Direct evidence of the association between intensified metastatic competency and overexpression of cathepsin D gene has been provided. Clinical investigations have indicated that the level of cathepsin D in primary breast cancer is correlated with recurrence and metastases and may be the best indicator of prognosis, independent of other parameters (Thorpe et al., 1989; Tandon et al., 1990).

## SUMMARY

Lysosomes are acidic intracellular vacuoles of heterogeneous shape, size, and content. Lysosomes contain hydrolytic enzymes that degrade proteins, lipids, carbohydrates, and nucleic acids derived from intracellular (through autophagy) and extracellular (through heterophagy) sources. Lysosomal degradation regulates several physiological cell functions. These include turnover of cellular organelles and extracellular constituents; amino acid and glucose homeostasis; processing of proteins; lipid metabolism; cell growth, differentiation, and involution; host defenses against microorganisms and other pathogens; and removal of necrotic and foreign material from the circulation and from tissues.

Lysosomal degradation also plays an important role in the pathophysiology of acute and chronic cell injury, inflammation and repair, and tumor growth and metastasis. The participation of the lysosomes in the specific types of cell injury we have discussed is due to altered regulation of one or more of the following processes: turnover of cellular organelles by autophagic degradation; levels and activities of lysosomal hydrolases; levels of intracellular and extracellular lysosomal hydrolase inhibitors; transport of degradation products from the lysosomal matrix to the cytosol; permeability of the lysosomal membrane to hydrolases; lysosomal vacuolar acidification; transport of degradable substrates and of pathogens to the lysosomes; transport and processing of secretory proteins and lysosomal hydrolases during biogenesis; traffic and fusion of lysosomal vacuoles and vesicles; secretion of lysosomal hydrolases; and accumulation of metals, particularly iron, acidotropic agents, and undegraded and/or undegradable materials in lysosomes.

## REFERENCES

- Andersen, K.-J., Haga, H.-J., and Dobrota, M. (1987). Lysosomes of the renal cortex: heterogeneity and role in protein handling. *Kidney Int.* 31, 886-897.
- Aoyagi, T. (1989). Biological significance of small molecular protease inhibitors from microorganisms. In: *Intracellular Proteolysis. Mechanisms and Regulations* (Katunuma, N. and Kominami, E., eds.), pp. 377-383, Scientific Societies Press, Tokyo, Japan.
- Badalamente, M.A., Hurst, L.C., and Stracher, A. (1989). Neuromuscular recovery using calcium protease inhibition after median nerve repair in primates. *Proc. Natl. Acad. Sci. USA* 86, 5983-5987.
- Ballard, F.J. (1987). Regulation of intracellular protein breakdown with special reference to cultured cells. In: *Lysosomes: Their Role in Protein Breakdown* (Glaumann, H. and Ballard, F.J., eds.), pp. 285-318, Academic Press, London.
- Ballard, F.J. and Gunn, J.M. (1982). Nutritional and hormonal effects on intracellular protein catabolism. *Nutri. Rev.* 40, 33-42.
- Baracos, V.E. and Goldberg, A.L. (1986). Maintenance of normal length improves protein balance and energy status in isolated rat skeletal muscles. *Am. J. Physiol.* 251, C588-C596.
- Baricos, W.H., Cortez, S.L., Le, Q.C., Wu, L.-T., Shaw, E., Hanada, K., and Shah, S.V. (1991). Evidence suggesting a role for cathepsin L in an experimental model of glomerulonephritis. *Arch. Biochem. Biophys.* 288, 468-472.

- Baricos, W.H. and Shah, S.V. (1989). Role of cathepsin B and L in antglomerular basement membrane nephritis in rats. *Renal Physiol. Biochem.* 12, 400-405.
- Baricos, W.H., Zhou, Y., Fuerst, R.S., Barrett, A.J., and Shah, S.V. (1987). The role of aspartic and cysteine proteinases in albumin degradation by rat kidney cortical lysosomes. *Arch. Biochem. Biophys.* 256, 687-691.
- Barrett, A.J. (1987). The cystatins: a new class of peptidase inhibitors. *Trends Biochem. Sci.* 12, 193-196.
- Bartolf, M. and Franson, R.C. (1990). Characterization and partial purification of soluble, lysosomal phospholipase(s) A<sub>2</sub> from adrenal medulla. *Biochim. Biophys. Acta* 1042, 247-254.
- Bassett, M.L., Halliday, J.W., and Powell, L.W. (1986). Value of hepatic iron measurements in early hemochromatosis and determinations of the critical iron level associated with fibrosis. *Hepatology* 6, 24-29.
- Berry, J.P., Meignan, M., Escaig, F., and Galle, P. (1988). Inhaled soluble aerosols insolubilized by lysosomes of alveolar cells. Applications to some toxic compounds; electron microprobe and ion microprobe studies. *Toxicology* 52, 127-139.
- Bird, J.W.C. and Roisen, F.J. (1986). Lysosomes in muscle: developmental aspects, enzyme activities, and role in protein turnover. In: *Myology*, Vol. 1 (Engel, A. and Banker, B., eds.), pp. 745-768, McGraw Hill, New York.
- Black, C.M., Paliescheskey, M., Beaman B.L., Donovan, R.M., and Goldstein, E. (1986). Acidification of phagosomes in murine macrophages: blockage by *Nocardia asteroides*. *J. Infect. Dis.* 154, 952-958.
- Bond, J.S. and Butler, P.E. (1987). Intracellular proteases. *Ann. Rev. Biochem.* 56, 333-364.
- Boyer, M. and Tannock, I.F. (1993). Lysosomes, lysosomal enzymes, and cancer. *Adv. Cancer Res.* 60, 269-291.
- Briozzo, P., Morisset, M., Capony, F., Rougeot, C., and Rochefort, H. (1988). In vitro degradation of extracellular matrix with M<sub>2</sub> 52,000 cathepsin D secreted by breast cancer cells. *Cancer Res.* 48, 3688-3692.
- Brown, M.S. and Goldstein, J.L. (1986). A receptor-mediated pathway for cholesterol homeostasis. *Science* 232, 34-47.
- Brown, W.J., Goodhouse, J., and Farguliar, G. (1986). Mannose-6-phosphate receptors for lysosomal enzymes cycle between the Golgi complex and endosomes. *J. Cell Biol.* 103, 1235-1247.
- Buktenica, S., Olenick, S., Salgia, R., and Frankfater, A. (1987). Degradation and regurgitation of extracellular proteins by cultured mouse peritoneal macrophages and baby hamster kidney fibroblasts. Kinetic evidence that the transfer of proteins to lysosomes is not irreversible. *J. Biol. Chem.* 262, 9469-9476.
- Burnside, J. and Schneider, D.L. (1982). Characterization of the membrane proteins of rat liver lysosomes. *Biochem. J.* 204, 525-534.
- Capony, F., Rougeot, C., Montcourrier, P., Cavallès, V., Salazar, G., and Rochefort, H. (1989). Increased secretion, altered processing, and glycosylation of pro-cathepsin D in human mammary cancer cells. *Cancer Res.* 49, 3904-3909.
- Chakraborty, P. and Das, P.K. (1989). Suppression of macrophage lysosomal enzymes after *Leishmania donovani* infection. *Biochem. Med. Met. Biol.* 41, 46-55.
- Chapman, H.A., Stone, O.L., and Vavrin, Z. (1984). Degradation of fibrin and elastin by intact human alveolar macrophages in vitro. *J. Clin. Invest.* 73, 806-815.
- Chen, J.M., Aimes, R.T., Ward, G.R., Youngleib, G.L., and Quigley, J.P. (1991). Isolation and characterization of 70-kDa metalloprotease (gelatinase) that is elevated in Rous sarcoma virus-transformed chicken embryo fibroblasts. *J. Biol. Chem.* 266 5113-5121.
- Chiang, C.-P. and Nilsen-Hamilton, M. (1986). Opposite and selective effects of epidermal growth factor and human platelet transforming growth factor- $\beta$  on the production of secreted proteins by murine 3T3 cells and human fibroblasts. *J. Biol. Chem.* 261, 10478-10481.
- Choudhuri, S., McKim, J.M., and Klaassen, C.D. (1992). Role of hepatic lysosomes in the degradation of metallothionein. *Toxicol. Appl. Pharmacol.* 115, 64-71.
- Cleton, M.I., de Bruijn, W.C., van Blokland, W.T.M., Marx, J.J.M., Roelofs, J.M., and Rademakers, L.H.P.M. (1988). Iron content and acid phosphatase activity in hepatic parenchymal lysosomes

- of patients with hemochromatosis before and after phlebotomy treatment. *Ultrastruct. Pathol.* 12, 161-174.
- Cras, P., Kawai, M., Lowery, D., Gonzalez-Dewhitt, P., Greenberg, B., and Perry, G. (1991). Senile plaque neurites in Alzheimer disease accumulate amyloid precursor protein. *Proc. Natl. Acad. Sci. USA* 88, 7552-7556.
- d'Azzo, A., Gillemans, N., and Galjart, N. (1989). The complex of  $\beta$ -galactosidase, neuraminidase and "protective protein" in lysosomes: molecular characterization of the "protective protein". In: *Molecular Basis of Membrane-Associated Diseases* (Azzi, A., Drahota, Z., and Papa, S., eds.), pp. 371-378, Springer-Verlag, New York.
- de Duve, C. (1983). Lysosomes revisited. *Eur. J. Biochem.* 137, 391-397.
- de Groen, P.C., LeSage, G.D., Tietz, P.S., and LaRusso, N.F. (1989). Purification and immunological quantification of rat liver lysosomal glycosidases. *Biochem. J.* 264, 115-123.
- Delaissé, J.-M., Ledent, P., and Vaes, G. (1991). Collagenolytic cysteine proteinases of bone tissue. Cathepsin B, (pro)cathepsin L and a cathepsin-like 70 kDa proteinase. *Biochem. J.* 279, 167-174.
- Del Rosso, M., Fibbi, G., Pucci, M., Dini, G., Grappone, C., and Nolli, M.L. (1991). Modulation of surface-associated urokinase: binding, interiorization, delivery to lysosomes, and degradation in human keratinocytes. *Exp. Cell Res.* 193, 346-355.
- Denhardt, D.T., Greenberg, A.H., Egan, S.E., Hamilton, R.T., and Wright, J.A. (1987). Cysteine protease cathepsin L expression correlates closely with the metastatic potential of H-ras-transformed murine fibroblasts. *Oncogene* 2, 55-59.
- Dice, J.F. (1989). Altered intracellular protein degradation in aging: a possible cause of proliferative arrest. *Exp. Gerontol.* 24, 451-459.
- Diment, S. and Stahl, P. (1985). Macrophage endosomes contain proteases which degrade endocytosed protein ligands. *J. Biol. Chem.* 260, 15311-15317.
- Dohm, G.L., Tapscott, E.B., and Kasperek, G.J. (1987). Protein degradation during endurance exercise and recovery. *Med. Sci. Sports Exerc.* 19, S166-S171.
- Dong, J., Prence, E.M., and Sahagian, G.G. (1989). Mechanism for selective secretion of a lysosomal protease by transformed mouse fibroblasts. *J. Biol. Chem.* 264, 7377-7383.
- Driscoll, J. and Goldberg, A.L. (1989). Skeletal muscle proteasome can degrade proteins in an ATP-dependent process that does not require ubiquitin. *Proc. Natl. Acad. Sci. USA* 86, 787-791.
- Dunn, W.A. (1990). Studies on the mechanisms of autophagy: formation of autophagic vacuoles. *J. Cell Biol.* 110, 1923-1933, 1990.
- Fagan, J.M., Waxman, L., and Goldberg, A.L. (1987). Skeletal muscle and liver contain a soluble ATP + ubiquitin-dependent proteolytic system. *Biochem. J.* 243, 335-343.
- Fenton-Hall, B., Webster, P., Ma, A.K., Joiner, K.A., and Andrews, N.W. (1992). Desialylation of lysosomal membrane glycoproteins by *Trypanosoma cruzi*: a role for the surface neuraminidase in facilitating parasite entry into the host cell cytoplasm. *J. Exp. Med.* 176, 313-325.
- Frick, K.K., Doherty, P.J., Gottesman, M.M., and Scher, C.D. (1985) Regulation of the transcript for a lysosomal protein: evidence for a gene program modified by platelet-derived growth factor. *Mol. Cell. Biol.* 5, 2582-2589.
- Fuller, S.J., Gaitanaki, C.J., and Sugden, P.H. (1989). Effects of increasing extracellular pH on protein synthesis and protein degradation in the perfused working rat heart. *Biochem. J.* 259, 173-179.
- Furuno, K. and Goldberg, A.L. (1986). The activation of protein degradation in muscle by  $Ca^{2+}$  or muscle injury does not involve a lysosomal mechanism. *Biochem. J.* 237, 859-864.
- Furuno, K., Goodman, M.N., and Goldberg, A.L. (1990). Role of different proteolytic systems in the degradation of muscle proteins during denervation atrophy. *J. Biol. Chem.* 265, 8550-8557.
- Gal, S., Willingham, M.C., and Gottesman, M.M. (1985). Processing and lysosomal localization of a glycoprotein whose secretion is transformation stimulated. *J. Cell Biol.* 100, 535-544.
- Galjaard, H. and Reuser, A.J. (1984). Genetic aspects of lysosomal storage diseases. In: *Lysosomes in Biology and Pathology* (Dingle, J.T., Dean, R.T., and Sly, W., eds.), pp. 315-345, Elsevier, New York.



- Galjart, N.J., Gillemans, N., Meijer, D., and d'Azzo, A. (1990). Mouse "protective protein". cDNA cloning, sequence comparison, and expression. *J. Biol. Chem.* 265, 4678-4684.
- Garcia, M., Derocq, D., Pujol, P., and Rochefort, H. (1990). Overexpression of transfected cathepsin D in transformed cells increases their malignant phenotype and metastatic potency. *Oncogene* 5, 1809-1814.
- Gay, S. and Koopman, W.J. (1989). Immunopathology of rheumatoid arthritis. *Curr. Opin. Rheumatol.* 1, 8-14.
- Gedigk, P. and Totovic, V. (1983). Lysosomes and lipopigments. In: *Cellular Pathobiology of Human Disease* (Trump, B.F., Laufer, A., and Jones, R.T., eds.), pp. 205-221, Gustav Fisher, New York.
- Geuze, H.J., Slot, J.W., Strous, G.T.A.M., Hasilik, A., von Figura, K. (1985). Possible pathways for lysosomal enzyme delivery. *J. Cell Biol.* 101, 2253-2262.
- Glaumann, H. and Marzella, L. (1981). Degradation of membrane components by Kupffer cell lysosomes. *Lab. Invest.* 45, 479-490.
- Goebel, H.H. and Busch, H. (1990). Abnormal lipopigments and lysosomal residual bodies in metachromatic leukodystrophy. In: *Lipofuscin and Ceroid Pigments* (Porta, E.A., ed.), pp. 299-309, Plenum Press, New York.
- Haga, H.-J. (1989). Kidney lysosomes. *Int. J. Biochem.* 21, 343-345.
- Hasselgren, P.-O., Talamini, M.A., James, J.H., and Fischer, J.E. (1986). Protein metabolism in different types of skeletal muscle during early and late sepsis in rats. *Arch. Surg.* 121, 918-923.
- Helseth, D.L., Jr. and Veis, A. (1984). Cathepsin D-mediated processing of procollagen: lysosomal enzyme involvement in secretory processing of procollagen. *Proc. Natl. Acad. Sci. USA* 81, 3302-3306.
- Himeno, M., Koutoku, H., Ishikawa, T., and Kato, K. (1989). Acid phosphatase in rat liver lysosomal membranes: purification and characterization. *J. Biochem.* 105, 449-456.
- Hiwasa, T., Sawada, T., Tanaka, K., Chiba, T., Tanaka, T., Kominami, E., Katunuma, N., and Sakiyama, S. (1991). Co-localization of *ras* gene products and cathepsin L in cytoplasmic vesicles in v-Ha-*ras*-transformed NIH3T3 mouse fibroblasts. *Biomed. Biochim. Acta*, 50, 576-585.
- Hoffman, K.E., Yanelli, K., and Bridges, K.R. (1991). Ascorbic acid and iron metabolism: alterations in lysosomal function. *Am. J. Clin. Nutr.* 54, 1188S-1192S.
- Hohman, T.C. and Bowers, B. (1984). Hydrolase secretion is a consequence of membrane recycling. *J. Cell Biol.* 98, 246-252.
- Hollas, W., Blasi, F., and Boyd, D. (1991). Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer. *Cancer Res.* 51, 3690-3695.
- Hopgood, M.F., Clark, M.G., and Ballard, F.J. (1981). Stimulation by glucocorticoids of protein degradation in hepatocyte monolayers. *Biochem. J.* 196, 33-40.
- Hussain, H., Dudley, G.A., and Johnson, P. (1987). Effects of denervation on calpain and calpastatin in hamster skeletal muscles. *Exp. Neurol.* 97, 635-643.
- Ishii, Y., Hashizume, Y., Watanabe, T., Waguri, S., Sato, N., Yamamoto, M., Hasegawa, S., Kominami, E., and Uchiyama, Y. (1991). Cysteine proteinases in bronchoalveolar epithelial cells and lavage fluid of rat lung. *J. Histochem. Cytochem.* 39, 461-468.
- Jensen, P.H., Christensen, E.I., Ebbesen, P., Gliemann, J., and Andreasen, P.A. (1990). Lysosomal degradation of receptor-bound urokinase-type plasminogen activator is enhanced by its inhibitors in human trophoblastic choriocarcinoma cells. *Cell Regul.* 1, 1043-1056.
- Jerome, W.G. and Lewis, J.C. (1985). Early atherogenesis in white Carneau pigeons. II. Ultrastructural and cytochemical observations. *Am. J. Pathol.* 119, 210-222.
- Jerome, W.G., Mino, L.K., Glick, J.M., Rothblat, G.H., and Lewis, J.C. (1991). Lysosomal lipid accumulation in vascular smooth muscle cells. *Exp. Mol. Pathol.* 54, 144-158.
- Jurilij, N. and Pfeifer, U. (1990). Inhibition of cellular autophagy in kidney tubular cells stimulated to grow by unilateral nephrectomy. *Virchows Arch. [B]* 59, 32-37.
- Kalina, M. and Socher, R. (1991). Endocytosis in cultured rat alveolar type II cells: effect of lysosomotropic weak bases on the processes. *J. Histochem. Cytochem.* 39, 1337-1348.

- Kaloyanides, G.J. and Pastoriza-Munoz, E. (1980). Aminoglycoside nephrotoxicity. *Kidney Int.* 18, 571-582.
- Kasperek, G.J. and Snider, R.D. (1989). Total and myofibrillar degradation in isolated soleus muscles after exercise. *Am. J. Physiol.* 257, E1-E5.
- Katunuma, N. and Kominami, E. (1987). Abnormal expression of lysosomal cysteine proteinases in muscle wasting diseases. *Rev. Physiol. Biochem. Pharmacol.* 108, 1-20.
- Keene, W.E., Hidalgo, M.E., Orozco, E., and McKerrow, J.H. (1990). *Entamoeba histolytica*: correlation of the cytopathic effect of virulent trophozoites with secretion of a cysteine proteinase. *Exp. Parasitol.* 71, 199-206.
- Keren, Z., and LeGrue, S.J. (1988). Identification of cell surface cathepsin B-like activity on murine melanomas and fibrosarcomas: modulation by butanol extraction. *Cancer Res.* 48, 1416-1421.
- Kesava-Reddy, G. and Dhar, S.C. (1991). Metabolism of glycosaminoglycans in tissues of adjuvant arthritic rat. *Mol. Cell. Biochem.* 106, 117-124.
- Kirschke, H. and Barrett, A.J. (1987). Chemistry of lysosomal proteases. In: *Lysosomes: Their Role in Protein Breakdown* (Glaumann, H. and Ballard, F.J., eds.), pp. 193-238, Academic Press, London.
- Klionsky, D.L., Herman, P.K., and Emr, S.D. (1990). The fungal vacuole: composition, function, and biogenesis. *Microbiol. Rev.* 54, 266-292.
- Koivunen, E., Ristimäki, A., Itkonen, O., Osman, S., Vuento, M., and Stenman, U.-H. (1991). Tumor-associated trypsin participates in cancer cell-mediated degradation of extracellular matrix. *Cancer Res.* 51, 2107-2112.
- Kominami, E., Tsukahara, T., Bando, Y., and Katunuma, N. (1987). Autodegradation of lysosomal cysteine proteases. *Biochem. Biophys. Res. Commun.* 144, 749-756.
- Kornfeld, S. (1990). Lysosomal enzyme targeting. *Biochem. Soc. Trans.* 18, 367-374.
- Kornfeld, S. and Mellman, I. (1989). The biogenesis of lysosomes, *Ann. Rev. Cell Biol.* 5, 483-525.
- Krogstad, D.J. and Schlesinger, P.H. (1987). Acid-vesicle function, intracellular pathogens, and the action of chloroquine against *Plasmodium falciparum*. *N. Engl. J. Med.* 317, 542-549.
- Kunze, H., Bohn, E., and Löffler, B.-M. (1988). Inhibitors of liver lysosomal acid phospholipase A<sub>1</sub>. *Eur. J. Biochem.* 177, 591-595.
- Kuriakose, N.R., Reifel, C.W., Bendayan, M., Elce, J.S., and Shin, S.H. (1989). Prolactin crinophagy is induced in the estrogen-stimulated male rat pituitary. *Histochem.* 92, 499-503.
- Lah, T.T., Clifford, J.L., Helmer, K.M., Day, N.A., Moin, K., Honn, K.V., Crissman, J.D., and Sloane, B.F. (1989). Inhibitory properties of low molecular mass cysteine proteinase inhibitors from human sarcoma. *Biochim. Biophys. Acta* 993, 63-73.
- Lau, M.M.H. and Neufeld, E.F. (1989). A frameshift mutation in a patient with Tay-Sachs disease causes premature termination and defective intracellular transport of the  $\alpha$ -subunit of  $\beta$ -hexosaminidase. *J. Biol. Chem.* 264, 21376-21380.
- Lee, H.-K. and Marzella, L. (1992). Transport of macromolecules to lysosomes. In: *Pathophysiology of Lysosomal Transport* (Thoene, J.G., ed.), pp. 231-293, CRC Press, Boca Raton.
- Lee, H.-K. and Marzella, L. (1994). Regulation of intracellular protein degradation with special reference to lysosomes: role in cell physiology and pathology. *Int. Rev. Exp. Pathol.* 35, 39-147.
- Lee, H.-K., Meyers, R.A., and Marzella, L. (1989). Stimulation of autophagic protein degradation by nutrient deprivation in a differentiated murine teratocarcinoma (F9 12-1a) cell line. *Exp. Mol. Pathol.* 50, 139-146.
- Lee, H.-K., Jones, R.T., Meyers, R.A., and Marzella, L. (1992). Regulation of protein degradation in normal and transformed human bronchial epithelial cells in culture. *Arch. Biochem. Biophys.* 296, 271-277.
- Lemons, R.M. and Thoene, J.G. (1991). Mediated calcium transport by isolated human fibroblast lysosomes. *J. Biol. Chem.* 266, 14378-14382.
- LeSage, G.D., Kost, L.J., Barham, S.S., and LaRusso, N.F. (1986). Biliary excretion of iron from hepatocyte lysosomes in the rat: a major excretory pathway in experimental iron overload. *J. Clin. Invest.* 77, 90-97.

- Li, S.-C., Sonnino, S., Tettamanti, G., and Li, Y.-T. (1988). Characterization of a nonspecific activator protein for the enzymatic hydrolysis of glycolipids. *J. Biol. Chem.* 263, 6588-6591.
- Link, G., Pinson, A., and Hershko, C. (1993). Iron loading of cultured cardiac myocytes modifies sarcolemmal structure and increases lysosomal fragility. *J. Lab. Clin. Med.* 121, 127-134.
- Löffler, B.-M. and Kunze, H. (1987). Fractionation, biochemical characterization and lysosomal phospholipases of human liver. *FEBS Lett.* 216, 51-56.
- Lougheed, M., Zhang, H., and Steinbrecher, U.P. (1991). Oxidized low density lipoprotein is resistant to cathepsins and accumulates within macrophages. *J. Biol. Chem.* 266, 14519-14525.
- Maciewicz, R.A. and Wotton, S.F. (1991). Degradation of cartilage matrix components by the cysteine proteinases, cathepsin B and L. *Biomed. Biochim. Acta* 50, 561-564.
- Mancini, G.M.S., Beerens, C.E.M., Aula, P.P., and Verheijen, F.W. (1991). Sialic acid storage diseases. A multiple lysosomal transport defect for acidic monosaccharides. *J. Clin. Invest.* 87, 1329-1335.
- Marks, D.L., Kost, L.J., Kuntz, S.M., Romero, J.C., and LaRusso, N.F. (1991). Hepatic processing of recombinant human renin: mechanisms of uptake and degradation. *Am. J. Physiol.* 261, G349-G358.
- Marzella, L. and Glaumann, H. (1987). Autophagy, microautophagy and crinophagy as mechanisms for protein degradation. In: *Lysosomes: Their Role in Protein Breakdown* (Glaumann, H. and Ballard, F.J., eds.), pp. 319-367. Academic Press, London.
- Matrisian, L.M. (1990). Metalloproteinases and their inhibitors in matrix remodeling. *Trends Genet.* 6, 121-125.
- Matsumoto, Y., Watanabe, T., Suga, T., and Fujitani, H. (1989). Inhibitory effects of quaternary ammonium compounds on lysosomal degradation of endogenous proteins. *Chem. Pharm. Bull.* 37, 516-518.
- Matsuzawa, Y. and Hostetler, K.Y. (1980). Properties of phospholipase C isolated from rat liver lysosomes. *J. Biol. Chem.* 255, 646-652.
- Mortimore, G.E. and Khurana, K.K. (1990). Regulation of protein degradation in the liver. *Int. J. Biochem.* 22, 1075-1080.
- Mortimore, G.E., Lardeux, B.R., and Adams, C.E. (1988). Regulation of microautophagy and basal protein turnover in rat liver. *J. Biol. Chem.* 263, 2506-2512.
- Mortimore, G.E. and Pösö, A.R. (1987). Intracellular protein catabolism and its control during nutrient deprivation and supply. *Ann. Rev. Nutr.* 7, 539-564.
- Mortimore, G.E., Pösö, A.R., and Lardeux, B.R. (1989). Mechanism and regulation of protein degradation in liver. *Diabetes Metab. Rev.* 5, 49-70.
- Müller, J., Pfeifer, U., and Dämmrich, J. (1987). Inhibited autophagic degradation during ACTH-stimulated growth of rat adrenal zona fasciculata. *Virchows Arch. [B]* 52, 429-441.
- Myers, B.M., Prendergast, F.G., Holman, R., Kuntz, S.M., and LaRusso, N.F. (1991). Alterations in the structure, physicochemical properties, and pH of hepatocyte lysosomes in experimental iron overload. *J. Clin. Invest.* 88, 1207-1215.
- Nakajima, M., Irimura, T., DiFerrante, N., and Nicolson, G.L. (1984). Melanoma cell heparanase. Characterization of heparan sulfate degradation fragments produced by B16 melanoma endoglucuronidase. *J. Biol. Chem.* 259, 2283-2290.
- Nakajima, M., Welch, D.R., Belloni, P.N., and Nicolson, G.L. (1987). Degradation of basement membrane type IV collagen and lung subendothelial matrix by rat mammary adenocarcinoma cell clones of differing metastatic potentials. *Cancer Res.* 47, 4869-4876.
- Nathalie, G., Véronique, D.-F., and Maurice, P. (1990). Digestion *in vitro* d'une membrane basale, la capsule de cristallin de boeuf, par les cathepsines, B, H et L du lysosome de foie humain et la cathepsine B tumorale du liquide d'ascite d'adénocarcinome ovarien. *Path. Biol.* 38, 988-992.
- Nie, Z.T., Lisjö, S., Åstrand, P.-O., and Henriksson, J. (1989). *In vitro* stimulation of the rat epitrochlearis muscle. II. Effects of catecholamines and nutrients on protein degradation and amino acid metabolism. *Acta Physiol. Scand.* 135, 523-529.
- Noda, T. and Farquhar, M.G. (1992). A non-autophagic pathway for diversion of ER secretory proteins to lysosomes. *J. Cell Biol.* 119, 85-97.

- O'Brien, J.S., Kretz, K.A., Dewji, N.N., Wenger, D.A., Esch, F., and Fluharty, A.L. (1988). Coding of two sphingolipid activator proteins (SAP-1 and SAP-2) by same genetic locus. *Science* 241, 1098-1101.
- Odessey, R. (1987). Regulation of lysosomal proteolysis in burn injury. *Metabolism* 36, 670-676.
- Ohkuma, S. (1987). The lysosomal proton pump and its effect on protein breakdown. In: *Lysosomes: Their Role in Protein Breakdown* (Glaumann, H. and Ballard, F.J., eds.), pp. 115-148, Academic Press, London.
- Oka, T., Ishida, T., Nishino, T., and Sugimachi, K. (1991). Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinoma. *Cancer Res.* 51, 3522-3525.
- Olbricht, C.J., James, K.C., and Tisher, C.G. (1987). Cathepsin B and L in nephron segments of rats with puromycin aminonucleoside nephrosis. *Kidney Int.* 32, 354-361.
- Oliver, C.N., Ahn, B.-W., Moerman, E.J., Goldstein, S., and Stadtman, E.R. (1987). Age-related changes in oxidized proteins. *J. Biol. Chem.* 262, 5488-5491.
- Olsson, G.M., Brunmark, A., and Brunk, U.T. (1989). Acridine orange-mediated photodamage of microsomal- and lysosomal fractions. *Virchows Arch. [B]* 56, 247-257.
- Oursler, M.J., Pederson, L., Pyfferoen, J., Osdoby, P., Fitzpatrick, L., and Spelsberg, T.C. (1993). Estrogen modulation of avian osteoclast lysosomal gene expression. *Endocrinol.* 132, 1373-1380.
- Pagano, M., Dalet-Fumeron, V., and Engler, R. (1989). The glycosylation state of the cathepsin B-like proteinase from human malignant ascitic fluid: possible implication in the secretory pathway of these proenzymes. *Cancer Lett.* 45, 13-19.
- Palestine, A.G., Austin, H.A., Balow, J.E., Antonovych, T.T., Sabnis, S.G., Preuss, H.G., and Nussenblatt, R.B. (1986). Renal histopathologic alterations in patients treated with cyclosporine for uveitis. *N. Engl. J. Med.* 314, 1293-1298.
- Palmer, D.N., Fearnley, I.M., Medd, S.M., Walker, J.E., Martinus, R.D., Bayliss, S.L., Hall, N.A., Lake, B.D., Wolfe, L.S., and Jolly, R.D. (1990). Lysosomal storage of DCCD reactive proteolipid subunit of mitochondrial ATP synthase in human and ovine ceroid lipofuscinoses. In: *Lipofuscin and Ceroid Pigments* (Porta, E.A., ed.), pp. 211-222, Plenum Press, New York.
- Papadopoulos, T. and Pfeifer, U. (1987). Protein turnover and cellular autophagy in growing and growth-inhibited 3T3 cells. *Exp. Cell Res.* 171, 110-121.
- Parkhouse, W.S. (1988). Regulation of skeletal muscle myofibrillar protein degradation: Relationship to fatigue and exercise. *Int. J. Biochem.* 20, 769-775.
- Patel, S.C. (1989). Genetic defects of lysosomal function in animals. *Ann. Rev. Nutr.* 9, 395-416.
- Pauza, C.D. and Price, T.M. (1988). Human immunodeficiency virus infection of T cells and monocytes proceeds via receptor-mediated endocytosis. *J. Cell Biol.* 107, 959-968.
- Paw, B.H., Moskowitz, S.M., Uhrhammer, N., Wright, N., Kaback, M.M., and Neufeld, E.F. (1990). Juvenile GM<sub>2</sub> gangliosidosis caused by substitution of histidine for arginine at position 499 or 504 of the  $\alpha$ -subunit of  $\beta$ -hexosaminidase. *J. Biol. Chem.* 265, 9452-9457.
- Payne, H.R., Storz, J., and Henk, W.G. (1990). Initial events in bovine coronavirus infection: analysis through immunogold probes and lysosomotropic inhibitors. *Arch. Virol.* 114, 175-189.
- Pillai, S. and Zull, J. (1986). Production of biologically active fragments of parathyroid hormone by isolated Kupffer cells. *J. Biol. Chem.* 261, 14919-14923.
- Porta, E.A. (1991). Advances in age pigment research. *Arch. Gerontol. Geriatr.* 12, 303-320.
- Reasor, M.J. (1989). A review of the biology and toxicologic implications of the induction of lysosomal lamellar bodies by drugs. *Toxicol. Appl. Pharmacol.* 97, 47-56.
- Reilly, J.J., Manson, R.W., Chen, P., Joseph, L.J., Sukhatme, V.P., Yee, R., and Chapman, H.A. (1989). Synthesis and processing of cathepsin L, an elastase, by human alveolar macrophages. *Biochem. J.* 257, 493-498.
- Resau, J.H., Marzella, L., Trump, B.F. and Jones, R.T. (1984). Degradation of zymogen granules by lysosomes in cultured pancreatic explants. *Am. J. Pathol.* 115, 139-150.

- Rhodes, C.H., Mezitis, S.G.E., Gonatas, N.K., and Fleischer, B. (1989). Selective effect of nerve growth factor on some Golgi and lysosomal enzyme activities of rat pheochromocytoma (PC12) cells. *Arch. Biochem. Biophys.* 272, 175-184.
- Rifkin, D.B., Tsuboi, R., and Mignatti, P. (1989). The role of proteases in matrix breakdown during cellular invasion. *Am. Rev. Respir. Dis.* 140, 1112-1113.
- Rocheftort, H., Capony, F., and Garcia, M. (1990). Cathepsin D: a protease involved in breast cancer metastasis. *Cancer Metastasis Rev.* 9, 321-331.
- Rodman, J.S., Stahl, P.D., and Gluck, S. (1991). Distribution and structure of the vacuolar H<sup>+</sup>-ATPase in endosomes and lysosomes from LLC-PK<sub>1</sub> cells. *Exp. Cell Res.* 192, 445-452.
- Rosenthal, P.J., Mckerrow, J.H., Aikawa, M., Nagasawa, H., and Leech, J.H. (1988). A malarial cysteine proteinase is necessary for hemoglobin degradation by *Plasmodium falciparum*. *J. Clin. Invest.* 82, 1560-1566.
- Rothman, J.H., Yamashiro, C.T., Raymond, C.K., Kane, P.M., and Stevens, T.H. (1989). Acidification of the lysosome-like vacuole and the vacuolar H<sup>+</sup>-ATPase are deficient in two yeast mutants that fail to sort vacuolar proteins. *J. Cell Biol.* 109, 93-100.
- Rousset, B. and Mornex, R. (1991). The thyroid hormone secretory pathway-current dogmas and alternative hypotheses. *Mol. Cell. Endocrinol.* 78, C89-C93.
- Rousset, B., Selmi, S., Alquier, C., Bourgeat, P., Orelle, B., Audebet, C., Rabilloud, R., Bernier-Valentin, F., and Munari-Silem, Y. (1989a). *In vitro* studies of the thyroglobulin degradation pathway: endocytosis and delivery of thyroglobulin to lysosomes, release of thyroglobulin cleavage products-iodotyrosines and iodothyronines. *Biochimie* 71, 247-262.
- Rousset, B., Selmi, S., Bornet, H., Bourgeat, P., Rabilloud, R., and Munari-Silem, Y. (1989b). Thyroid hormone residues are released from thyroglobulin with only limited alteration of the thyroglobulin structure. *J. Biol. Chem.* 264, 12620-12626.
- Sakaida, I., Kyle, M., and Farber, J.L. (1990). Autophagic degradation of protein generates a pool of ferric iron required for the killing of cultured hepatocytes by an oxidative stress. *Mol. Pharmacol.* 37, 435-442.
- Sandhoff, K., Conzelmann, E., Neufeld, E.F., Kaback, M.M., and Suzuki, K. (1989). The GM<sub>2</sub> gangliosidosis. In: *Metabolic Basis of Inherited Disease* (Scriver, C.R., Beaudet, A.L., Sly, W.S., and Valle, D., eds.), pp. 1807-1839, McGraw Hill, New York.
- Schneider, D.L. (1987). The proton pump ATPase of lysosomes and related organelles of the vacuolar apparatus. *Biochim. Biophys. Acta* 895, 1-10.
- Schnell, A.H., Swenne, I., and Borg, L.A.H. (1988). Lysosomes and pancreatic islet function. A quantitative estimation of crinophagy in the mouse pancreatic B-cell. *Cell Tissue Res.* 252, 9-15.
- Schwarze, P.E. and Seglen, P.O. (1985). Reduced autophagic activity, improved protein balance and enhanced *in vitro* survival of hepatocytes isolated from carcinogen-treated rats. *Exp. Cell Res.* 157, 15-28.
- Seglen, P.O. and Bohley, P. (1992). Autophagy and other vacuolar protein degradation mechanisms. *Experientia* 48, 158-172.
- Seglen, P.O., Gordon, P.B., Holen, I., and Høyvik, H. (1991). Hepatocytic autophagy. *Biomed. Biochim. Acta* 50, 373-381.
- Shih, V.E., Axel, S.M., Tewksbury, J.C., Watkins, D., Cooper, B.A., and Rosenblatt, D.S. (1989). Defective lysosomal release of vitamin B<sub>12</sub> (cb1F): a hereditary cobalamin metabolic disorder associated with sudden death. *Am. J. Med. Genet.* 33, 555-563.
- Sibley, L.D., Weidner, E., and Krahenbuhl, J.L. (1985). Phagosome acidification blocked by intracellular *Toxoplasma gondii*. *Nature* 315, 416-419.
- Sloane, B.F., Moin, K., Krepela, E., and Rozhin, J. (1990). Cathepsin B and its endogenous inhibitors: the role in tumor malignancy. *Cancer Metastasis Rev.* 9, 333-352.
- Snider, G.L., Ciccolella, D.E., Morris, S.M., Stone, P.J., and Lucey, E.C. (1991). Putative role of neutrophil elastase in the pathogenesis of emphysema. In: *Pulmonary Emphysema. The Rationale for Therapeutic Intervention* (Weinbaum, G., Giles, R.E., and Krell, R.D., eds.), Vol. 624, pp. 45-59, The New York Academy of Sciences, New York.

- Stål, P., Glaumann, H., and Hultcrantz, R. (1990). Liver cell damage and lysosomal iron storage in patients with idiopathic hemochromatosis. A light and electron microscopic study. *J. Hepatol.* 11, 172-180.
- Stein, G., Laske, V., Müller, A., Bräunlich, H., Lin, W., and Fleck, C. (1987). Aluminum induced damage of the lysosomes in the liver, spleen and kidneys of rats. *J. Applied Toxicol.* 7, 253-258.
- Sterr, M.L. and Meldolesi, J. (1987). The cell biology of experimental pancreatitis. *N. Engl. J. Med.* 316, 144-150.
- Tabas, I., Rosoff, W.J., and Boykow, G. (1987). ACAT in macrophages utilizes a cellular pool of cholesterol oxidase-accessible cholesterol as substrate. *J. Biol. Chem.* 263, 1266-1272.
- Tagawa, K., Maruyama, K., and Ishiura, S. (1992). Amyloid  $\beta$ /A4 precursor protein (APP) processing in lysosomes. *Ann. New York Acad. Sci.* 674, 129-137.
- Tanaka, M., Iio, T., and Tabata, T. (1988). Cupric ion-dependent inhibition of lysosomal acid cholesteryl ester hydrolase in the presence of hydroxylamine. *Lipids* 23, 126-130.
- Tandon, A.K., Clark, G.M., Chamness, G.C., Chirgwin, J.M., and McGuire, W.L. (1990). Cathepsin D and prognosis in breast cancer. *N. Engl. J. Med.* 322, 297-302.
- Tangirala, R.K., Mahlberg, F.H., Glick, J.M., Jerome, W.G., and Rothblat, G.H. (1993). Lysosomal accumulation of unesterified cholesterol in model macrophage foam cells. *J. Biol. Chem.* 268, 9653-9660.
- Tardieux, I., Webster, P., Ravesloot, J., Boron, W., Lunn, J.A., Heuser, J.E., and Andrews, N.W. (1992). Lysosome recruitment and fusion are early events required for trypanosome invasion of mammalian cells. *Cell* 71, 1117-1130.
- Tawa, N.E., Kettlehut, I.C., and Goldberg, A.L. (1992). Dietary protein deficiency reduces lysosomal and nonlysosomal ATP-dependent proteolysis in muscle. *Am. J. Physiol.* 263, E326-334.
- Teichert, U., Mechler, B., Müller, H., and Wolf, D.H. (1989). Lysosomal (vacuolar) proteinases of yeast are essential catalysts for protein degradation, differentiation, and cell survival. *J. Biol. Chem.* 264, 16037-16045.
- Thoene, J.S.(ed.) (1992). *Pathophysiology of Lysosomal Transport*, CRC Press, Boca Raton.
- Thomas, G.J. and Davies, M. (1989). The potential role of human kidney cysteine proteinases in glomerular basement membrane degradation. *Biochim. Biophys. Acta* 990, 246-253.
- Thorpe, S.M., Rochefort, H., Garcia, M., Freiss, G., Christensen, I.J., Khalaf, S., Paolucci, F., Pau, B., Rasmussen, B.B., and Rose, C. (1989). Association between high concentration of 52,000 cathepsin D and poor prognosis in primary human breast cancer. *Cancer Res.* 49, 6008-6014.
- Tietze, F., Seppala, R., Renlund, M., Hopwood, J.J., Harper, G.S., Thomas, G.H., and Gahl, W.A. (1989). Defective lysosomal egress of free sialic acid (*N*-acetylneuraminic acid) in fibroblasts of patients with infantile free sialic acid storage disease. *J. Biol. Chem.* 264, 15316-15322.
- Trabandt, A., Aicher, W., Gay, R. Sukhatme, V.P., Nilson-Hamilton, M., Hamilton, R.T., McGhee, J.R., Fassbender, H.G., and Gay, S. (1990). Expression of the collagenolytic and *ras*-induced cysteine proteinase cathepsin L and proliferation-associated oncogenes in synovial cells of *MRL/l* mice and patients with rheumatoid arthritis. *Matrix* 10, 349-361.
- Tsuboi, M., Harasawa, K., Izawa, T., Komabayashi, T., Fujinami, H., and Suda, K. (1993). Intralysosomal pH and release of lysosomal enzymes in the rat liver after exhaustive exercise. *J. Appl. Physiol.* 74, 1628-1634.
- Tsushima, H., Ueki, A., Matsuoka, Y., Mihara, H., and Hopsu-Havu, V.K. (1991). Characterization of a cathepsin-H-like enzyme from a human melanoma cell line. *Int. J. Cancer* 48, 726-732.
- Turner, R.R., Westwood, T., Regen, C.M., and Steinhardt, R.A. (1988). Increased protein degradation results from elevated free calcium levels found in muscle from *mdx* mice. *Nature* 335, 735-738.
- Uchiyama, Y., Nakajima, M., Muno, D., Watanabe, T., Ishii, Y., Waguri, S., Sato, N., and Kominami, E. (1990). Immunocytochemical localization of cathepsins B and H in corticotrophs and melanotrophs of rat pituitary gland. *J. Histochem. Cytochem.* 38, 633-639.
- Ueno, T., Muno, D., and Kominami, E. (1991). Membrane markers of endoplasmic reticulum preserved in autophagic vacuole membranes isolated from leupeptin-administered rat liver. *J. Biol. Chem.* 266, 18995-18999.

- Ulevitch, R.J. (1991). Recognition of bacterial endotoxin in biologic systems. *Lab. Invest.* 65, 121-122.
- Vignon, F., Capony, F., Chambon, M., Freiss, G., Garcia, M., and Rochefort, H. (1986). Autocrine growth stimulation of the MCF7 breast cancer cells by the estrogen-regulated 52K protein. *Endocrinol.* 118, 1537-1545.
- Wang, P.-H., Do, Y.-S., Macaulay, L., Shinagawa, T., Anderson, P.W., Baxter, J.D., and Hsueh, W.A. (1991). Identification of renal cathepsin B as a human prorenin-processing enzyme. *J. Biol. Chem.* 266, 12633-12638.
- Warner, T.G., Dambach, L.M., Shin, J.H., and O'Brien, J.S. (1981). Purification of the lysosomal acid lipase from human liver and its role in lysosomal lipid hydrolysis. *J. Biol. Chem.* 256, 2952-2957.
- Watanabe, M., Higashi, T., Hashimoto, M., Tomoda, I., Tominaga, S., Hashimoto, N., Morimoto, S., Yamauchi, Y., Nakatsukasa, H., and Kobayashi, M. (1987). Elevation of tissue cathepsin B and L activities in gastric cancer. *Hepatogastroenterology* 34, 120-122.
- Wedeen, R.P., Batuman, V., Cheeks, C., Marquet, E., and Sobel, H. (1983). Transport of gentamicin in rat proximal tubule. *Lab. Invest.* 48, 212-223.
- Weiler, R., Steiner, H.-J., Schmid, K.W., Obendorf, D., and Winkler, H. (1990). Glycoprotein II from adrenal chromaffin granules is also present in kidney lysosomes. *Biochem. J.* 272, 87-92.
- Weiss, E. The biology of rickettsiae. (1982). *Ann. Rev. Microbiol.* 36, 345-370.
- Whiting, P.H., Thomson, A.W., Blair, J.T., and Simpson, J.G. (1982). Experimental cyclosporine A nephrotoxicity. *Br. J. Exp. Pathol.* 63, 88-94.
- Willemer, S. and Adler, G. (1991). Mechanism of acute pancreatitis. *Int. J. Pancreatol.* 9, 21-30.
- Willemer, S., Bialek, R., and Adler, G. (1990). Localization of lysosomal and digestive enzymes in cytoplasmic vacuoles in caerulein-pancreatitis. *Histochem.* 94, 161-170.
- Wittels, M. and Spear, P.G. (1990). Penetration of cells by herpes simplex virus does not require a low pH-dependent endocytic pathway. *Virus Res.* 18, 271-290.
- Yamamoto, A., Masaki, R., Fukui, Y., and Tashiro, Y. (1990a). Absence of cytochrome P-450 and presence of autolysosomal membrane antigens on the isolation membranes and autophagolysosomal membranes in rat hepatocytes. *J. Histochem. Cytochem.* 38, 1571-1581.
- Yamamoto, A., Masaki, R., and Tashiro, Y. (1990b). Characterization of the isolation membranes of autophagosomes in rat hepatocytes by lectin cytochemistry. *J. Histochem. Cytochem.* 38, 573-580.
- Yu, Q.-C. and Marzella, L. (1986). Modification of lysosomal proteolysis in mouse liver with taxol. *Am. J. Pathol.* 122, 553-561.
- Yu, Q.-C. and Marzella, L. (1990). Pathobiology of lysosomes. In: *Cell Death: Mechanisms of Acute and Lethal Cell Injury* (Mergner, W.J. Jones, R.T., and Trump, B.F., eds.), pp. 143-178, Field & Wood, New York.
- Zeman, R.J., Kameyama, T., Matsumoto, K., Bernstein, P., and Etlinger, J.D. (1985). Regulation of protein degradation in muscle by calcium. Evidence for enhanced nonlysosomal proteolysis associated with elevated cytosolic calcium. *J. Biol. Chem.* 260, 13619-13624.
- Ziff, M. (1989). Pathway of mononuclear cell infiltration in rheumatoid synovitis. *Reumatol. Int.* 9, 97-103.

## RECOMMENDED READINGS

- Cataldo, A.M., Hamilton, D.J., Barrett, J.L., Paskenich, P.A., and Nixon, R.A. (1996). Abnormalities of the endosomal-lysosomal system in Alzheimer's disease: Relationship to disease pathogenesis. *Adv. Exptl. Med. Biol.* 389, 271-280.
- Kuchler, K., Rubartelli, A., and Holland, B. (Eds.) (1997). *Unusual Secretory Pathways; From Bacteria to Man*. Chapman and Hall, New York.
- Lloyd, J.B. and Mason, R.W. (Eds.) (1996). *Biology of the Lysosome*. Plenum Press, New York.
- Ollinger, K. and Brunk, U.T. (1995). Cellular injury induced by oxidative stress is mediated through lysosomal damage. *Free Rad. Biol. Med.* 19, 565-574.